Table 3. Secondary End Points.
| Levosimendan (n = 167) |
Placebo (n = 168)a |
P Value | |
|---|---|---|---|
| Mortality, No. (%) | |||
| In-hospital death | 10 (6) | 12 (7) | .59 |
| Mortality at day 28 | 12 (7) | 9 (5) | .39 |
| Mortality at day 180 | 14 (8) | 16 (10) | .59 |
| Survival, length of stay, and treatment outcomes, median (IQR) [range], d | |||
| Days alive out-of-hospital at day 28 | 16 (9-20) [0-24] | 16 (11-19) [0-23] | .31 |
| Days alive out of ICU at day 28 | 24 (21-26) [0-28] | 24 (22-25) [0-27] | .33 |
| Length of ICU stay | 4 (2-7) [0-61] | 4 (3-6) [1-42] | .41 |
| Length of hospital stay | 7 (5-10) [1-134] | 7 (5-10) [2-86] | .73 |
| Days without ventilator at day 28 | 11 (8-16) [3-138] | 10 (8-14) [2-87] | .46 |
| Duration of catecholamine treatment | 2 (1-4) [0-23] | 3 (2-5) [0-32] | .18 |
| Duration of renal replacement therapy | 4 (3-5) [1-9] | 4 (3-6) [1-30] | .43 |
| No. of days with circulatory mechanical assist device | 4 (2-5) [1-17] | 4 (2-5) [0-32] | .18 |
| No. of renal replacement therapy kits used, mean (SD) [range]b | 1.7 (1.0) [1-4] | 1.8 (1.0) [1-4] | .84 |
Abbreviation: ICU, intensive care unit.
a
Two patients in the placebo group refused participation after randomization.
b
A renal replacement kit corresponds to disposable circuit and filter used for dialysis.